Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug development

Targeting disease in the developing world

A new report by the Access to Medicine Index finds pharmaceutical companies influence access to medicines in developing countries through the development of innovative and adapted products, operating equitable pricing strategies and building local capacity.

More than half of the 327 products in development at the 20 largest pharmaceutical companies target five conditions; broadly reflecting the focus of available products, although new treatments are now being developed for several neglected diseases.

Endemic diseases being targeted

Source: Data and insight, Access to Medicine Index 2014

More than half of the 327 products in development at the 20 largest pharmaceutical companies target five conditions; broadly reflecting the focus of available products, although new treatments are now being developed for several neglected diseases.

The vast majority of products applicable to developing countries are for infectious diseases. Although there are several drugs for non-communicable diseases in development, most companies struggle to demonstrate how these products will be accessible to pa

Pipeline and marketed products

Source: Data and insight, Access to Medicine Index 2014

The vast majority of products applicable to developing countries are for infectious diseases. Although there are several drugs for non-communicable diseases in development, most companies struggle to demonstrate how these products will be accessible to patients in developing countries.

Since 2012, 11 companies have been granted regulatory approval by the US Food and Drug Administration or the European Medicines Agency for 30 new products for diseases relevant to developing countries

Regulatory approvals

Source: Data and insight, Access to Medicine Index 2014

Since 2012, 11 companies have been granted regulatory approval by the US Food and Drug Administration or the European Medicines Agency for 30 new products for diseases relevant to developing countries

Burden of the top five disease Among these five commonly targeted diseases, the communicable diseases have a higher burden in poorer countries. However, the burden of disease for the non-communicable conditions targeted is shared more equally.

Burden of the top five diseases

Source: World Health Organization

Among these five commonly targeted diseases, the communicable diseases have a higher burden in poorer countries. However, the burden of disease for the non-communicable conditions targeted is shared more equally.

The 20 largest research-based pharmaceutical companies are active in 75 developing countries in at least one of four areas: research and development; quality management in manufacturing; supply chain management; and pharmacovigilance.

Capacity building

Source: Data and insight, Access to Medicine Index 2014

The 20 largest research-based pharmaceutical companies are active in 75 developing countries in at least one of four areas: research and development; quality management in manufacturing; supply chain management; and pharmacovigilance.

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Pricing and donation

Source: Data and insight, Access to Medicine Index 2014

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Pricing and donation

Source: Data and insight, Access to Medicine Index 2014

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Pricing and donation

Source: Data and insight, Access to Medicine Index 2014

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Pricing and donation

Source: Data and insight, Access to Medicine Index 2014

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067466

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Burden of the top five disease Among these five commonly targeted diseases, the communicable diseases have a higher burden in poorer countries. However, the burden of disease for the non-communicable conditions targeted is shared more equally.
  • The 20 largest research-based pharmaceutical companies are active in 75 developing countries in at least one of four areas: research and development; quality management in manufacturing; supply chain management; and pharmacovigilance.
  • More than half of the 327 products in development at the 20 largest pharmaceutical companies target five conditions; broadly reflecting the focus of available products, although new treatments are now being developed for several neglected diseases.
  • The vast majority of products applicable to developing countries are for infectious diseases. Although there are several drugs for non-communicable diseases in development, most companies struggle to demonstrate how these products will be accessible to pa
  • Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.
  • Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.
  • Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.
  • Since 2012, 11 companies have been granted regulatory approval by the US Food and Drug Administration or the European Medicines Agency for 30 new products for diseases relevant to developing countries
  • regulatory-approvals-2

Supplementary information

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.